Gossamer bio announces fourth quarter and full-year 2024 financial results and provides business update

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced its financial results for the fourth quarter and year ended december 31, 2024, and provided a business update. “as we close the book on 2024 and embrace the promise of 2.
GOSS Ratings Summary
GOSS Quant Ranking